Compare Sanofi SA (SNY) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vanguard Dividend Appreciation Index Fund ETF trades at $236.97. The key difference: Sanofi SA pays a 5.5% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VIG | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | — |
52-Week High | $52.34 | $239.13 |
52-Week Low | $41.33 | $204.09 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $235.95, down 0.7% on the day, with a neutral technical signal and bullish moving averages. The ETF focuses on dividend growth from financially healthy U.S. large-caps, offering a low 0.04% expense ratio. Recent news highlights its role in diversifying Magnificent Seven exposure and building passive income, with a dividend scheduled for June 2026.
Outlook remains stable for long-term investors seeking quality dividend growth, though competition from higher-yield ETFs presents a risk. The neutral technical stance suggests near-term consolidation, while fundamental strength in holdings supports steady appreciation. Market sentiment is positive amid focus on reliable income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
